Gerberding Julie L.
SEC CIK 1628884 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| MRK | Merck & Co. | EVP, Chief Patient Off | 48.7K | — | $8.46M | 3 | 2021-11-01 | 2022-02-24 |
Most active insiders at MRK, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Zachary Jennifer | EVP, GC | — | $25.20M |
| 2 | DeLuca Richard R. | EVP, Pres, Merck Animal Heallth | — | $11.29M |
| 3 | Guindo Chirfi | EVP, Access, Policy, Comms | — | $8.15M |
| 4 | Williams David Michael | EVP, Chief Info, Digital Off | — | $8.13M |
| 5 | Davis Robert M | COB, CEO, Pres, Dir | — | $5.60M |
| 6 | Litchfield Caroline | EVP, CFO | — | $5.02M |
| 7 | Li Dean Y | Pres, Executive VP, MRL | — | $2.99M |
| 8 | Maraldo David R. | EVP, Pres. MMD | — | $2.41M |
| 9 | Oosthuizen Johannes Jacobus | Pres, U.S. Market | — | $1.83M |
| 10 | Smart Dalton E. III | SVP Fin. - Gbl Ctrl | — | $766.0K |
Gerberding Julie L. made no open-market trades at MRK in the last 12 months.
Transactions 3
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-02-28 | 2022-02-24 | MRK | Merck & Co. | Gerberding Julie L. | EVP, Chief Patient Off | A - Grant | $73.51 | +9,550 | 48.7K | +24% | +$702.0K | |
| DM | 2021-11-03 | 2021-11-01 | MRK | Merck & Co. | Gerberding Julie L. | EVP, Chief Patient Off | M - OptEx | $0.00 | +96.3K | 135.4K | +246% | $0 |
| D | 2021-11-03 | 2021-11-01 | MRK | Merck & Co. | Gerberding Julie L. | EVP, Chief Patient Off | S - Sale+OE | $87.91 | -96.3K | 39.2K | -71% | -$8.46M |
Purchase Sale Sale after option exercise All abbreviations